Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3633129 | 0.83 | APLNR (0.46) | RAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL3716792 | 0.81 | ALDH1A1 (0.38) | RAB9AKDM4ESMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL2846514 | 0.77 | HIF1A (0.51) | RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL5779927 | 0.77 | ALDH1A1 (0.44) | RAB9AKDM4EPOLBSMN1; SMN2APOBEC3A | |
| SCHEMBL18990622 | 0.76 | HDAC3 (0.41) | RAB9AKDM4EALDH1A1TSHRNPC1 | |
| SCHEMBL18260830 | 0.75 | NPC1 (0.42) | RAB9AKDM4ESMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL26970720 | 0.75 | TSHR (0.45) | KDM4EHSD17B10ALDH1A1TSHR | |
| SCHEMBL20876682 | 0.74 | HDAC3 (0.39) | RAB9AKDM4EPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL16540928 | 0.74 | GLA (0.40) | RAB9AKDM4EPOLBSMN1; SMN2APOBEC3A | |
| SCHEMBL2947631 | 0.74 | AGBL2 (0.36) | RAB9AKDM4EPOLBSMN1; SMN2APOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3555079-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | Isocure Biosciences Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018118793-A1 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF | ISOCURE BIOSCIENCES INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20100105702-A1 | Heterocyclylethylamide derivatives | BAYER CROPSCIENCE AG (DE) | 2010-04-29 | — | — | US | disclosed |
| US-20090093490-A1 | HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
| EP-1888535-B1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-11-19 | — | — | EP | disclosed |
| EP-1888535-A1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | Bayer CropScience S.A. (FR) | 2008-02-20 | — | — | EP | disclosed |
| EP-1879871-A1 | NEW HETEROCYCLYLETHYLAMIDE DERIVATIVES | Bayer CropScience S.A. (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117358-A9 | NEW HETEROCYCLYLETHYLAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2007-10-18 | — | — | WO | disclosed |
| WO-2006117356-A1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117358-A1 | NEW HETEROCYCLYLETHYLAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093490-A1 | HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | CYP1A2, CYP51A1, CYP1B1 | RAB9A 1276/4885KDM4E 1506/4885POLB 2079/4885 |
| US-20100105702-A1 | Heterocyclylethylamide derivatives | CYP1A2, CYP3A7, CYP51A1 | RAB9A 1633/4885KDM4E 1682/4885POLB 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.